- Home
- MAS vs CNTX Comparison
MAS vs CNTX Comparison
Compare MAS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAS | CNTX |
|---|---|---|
| Founded | 1929 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 209.5M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MAS | CNTX |
|---|---|---|
| Price | $61.59 | $3.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | ★ $75.86 | $6.00 |
| AVG Volume (30 Days) | ★ 2.2M | 836.9K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | 2.66 | ★ 69.33 |
| EPS | ★ 3.86 | N/A |
| Revenue | ★ $7,562,000,000.00 | N/A |
| Revenue This Year | $2.80 | N/A |
| Revenue Next Year | $3.38 | N/A |
| P/E Ratio | $15.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.55 | $0.49 |
| 52 Week High | $79.19 | $3.30 |
Technical Indicators
Market Signals| Indicator | MAS | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.87 | 69.05 |
| Support Level | $60.04 | $2.07 |
| Resistance Level | $65.98 | N/A |
| Average True Range (ATR) | 2.01 | 0.26 |
| MACD | -1.23 | 0.06 |
| Stochastic Oscillator | 7.69 | 83.09 |
Price Performance
Historical ComparisonAbout MAS Masco Corporation
Masco manufactures a variety of home improvement and building products. The company's $5 billion plumbing segment, led by the Delta and Hansgrohe brands, sells faucets, showerheads, and other related plumbing fixtures and components. The roughly $3 billion decorative architectural segment primarily sells paints and other coatings under the Behr and Kilz brands, but it also sells builder hardware products.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.